|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01498 PURAPHARM
Nominal 
0.570 +0.010 (+1.786%) | 2024/06 - Interim HKD(K$) | %Chg (Compare to Interim) | 2023/12 HKD(K$) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | 2020/12 HKD(K$) | |
| Turnover | 207,627 | 6.431% | 406,859 | 448,069 | 659,592 | 601,815 |
| Cost of Sales | (94,365) | 13.479% | (190,230) | (185,365) | (236,239) | (231,866) |
| Gross Profit | 113,262 | 1.195% | 216,629 | 262,704 | 423,353 | 369,949 |
| 2024/06 - Interim HKD(K$) | %Chg (Compare to Interim) | 2023/12 HKD(K$) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | 2020/12 HKD(K$) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | (12,804) | (3,022) | -- | (229) | |
| Change in FV & Impairment on Others | 1,264 | -- | (8,083) | (11,906) | (84,624) | (10,831) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (149) | -- | (145) | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | (14,765) | -59.563% | (102,312) | (119,182) | (117,192) | 40,217 | |
| Taxation | (3,921) | 237.726% | (3,769) | (1,032) | (4,685) | (8,507) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (18,686) | -50.402% | (106,081) | (120,214) | (121,877) | 31,710 | |
| 2024/06 - Interim HKD(K$) | %Chg (Compare to Interim) | 2023/12 HKD(K$) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | 2020/12 HKD(K$) | |
| Net Finance Costs / (Income) | 12,942 | -0.934% | 27,114 | 23,708 | 26,667 | 26,374 |
| Depreciation & Amortisation | 21,696 | 1.459% | 48,591 | 48,661 | 50,139 | 47,626 |
| Directors' Emoluments | -- | -- | 11,677 | 7,354 | 12,470 | 11,658 |
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified (Modified Report) | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | -4.730 | -50.419% | -26.850 | -30.470 | -30.950 | 8.550 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | 0.202 | 0.224 | (0.037) | 0.323 |
| NBV per share ($) | 0.330 | -- | 0.387 | 0.652 | 1.017 | 1.296 |
| Remarks: | Real time quote last updated: 24/12/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders ($) | HKD -18,686,000 |
| %Change | -50.402% |
| EPS / (LPS) | HKD -0.047 |
| NBV Per Share ($) | HKD 0.330 |